Is your organization missing one of the biggest cost savings opportunities in healthcare today?

Effectively treating Sleep Apnea will yield a greater than 20% PMPM reduction in the First Year1

Learn More About the Problem
Discover the Solution
Sleep Apnea Prevalence in Common Comorbidities

Members with Untreated vs. Treated Sleep Apnea
are 200% more expensive1

Each year millions of dollars are spent on testing and treatment for sleep apnea, yet just over 1 in 5 of those diagnosed with sleep apnea actually get better. We’re changing that!

Prevalence of Sleep Apnea in Chronic Conditions

Sleep apnea is prevalent in roughly three of four people with healthcare’s most common and expensive conditions.

  • 80% of people suffering from sleep apnea are undiagnosed

  • Diagnosing and initiating sleep apnea treatment costs $2,500-$10,000 per member

  • 22% remain adherent to treatment through the first 12 months

  • 12 continuous months of treatment results in 22%+ PMPM savings

Untreated sleep apnea diminishes the impact of ANY investment to improve the health of members with these high-cost conditions. 

Your key to unlocking 20%+ PMPM medical spend reduction1

EnsoTherapy helps leaders of health plans, ACOs, and at-risk provider organizations reduce medical spend and minimize acute care utilization.

EnsoTherapy doesn’t simply address treatment adherence issues, the solution actively predicts and prevents them, delivering immediate medical cost reductions and improved health outcomes for members on CPAP in your patient population. 

Benefits of Successfully Treated Sleep Apnea include:

  • Greater than 20% PMPM reduction in the first year on current sleep apnea population

  • Improve health in chronic, high-cost populations

  • Improve member experience and retention

Positively Impact Your Bottom Line with EnsoTherapy

EnsoTherapy is designed to generate a positive ROI for organizations in year one, focused on the already identified moderate and severe sleep apnea members in whom you have invested millions of dollars to test and diagnose.

By effectively increasing the 3 percent of the population that is adherent to treatment, successful health plan, ACO, and at-risk provider organizations save money.

Simply fill out our form and a team member will reach out to schedule a meeting at your convenience. 

During the meeting, we’ll discuss how to save your organization more than 20% on your existing sleep apnea population’s PMPM spend.

Review sources listed above.

Discover How:

"*" indicates required fields

Name*
Consent*

Select Research Highlighting the Untreated Sleep Apnea Opportunity

Sleep Apnea Treatment Cost Savings

In this newly published study from Mayo Clinic (Apr 2022), patients with obstructive sleep apnea (OSA) and comorbid cardiovascular disease (CVD) who were effectively treated for OSA were nearly $4,500 less expensive than those not adherent with their OSA treatment.

The High Cost of Untreated OSA

This University of Maryland study concludes that Medicare patients with untreated OSA demonstrated increased healthcare utilization and costs across all points of service relative to control patients, demonstrated higher total annual costs of $19,566 on average, in fully-adjusted models.

Ready to Connect?